Thieme E-Books & E-Journals -
Zurück
Z Gastroenterol 2021; 59(08): e253
DOI: 10.1055/s-0041-1733733
HCC und CCC
Freitag, 17. September 2021, 15:00-16:20 Uhr, Saal 4
Gastroenterologische Onkologie

IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)

P Galle
1   Universitätsklinik Mainz, I. Medizinische Klinik und Poliklinik, Mainz, Deutschland
,
RS Finn
2   Jonsson Comprehensive Cancer Center, Geffen School of Medicine at UCLA, Los Angeles, Vereinigte Staaten von Amerika
,
S Qin
3   People’s Liberation Army Cancer Center, Jinling Hospital, Nanjing, China
,
M Ikeda
4   National Cancer Center Hospital East, Kashiwa, Japan
,
M Ducreux
5   Gustave Roussy, Villejuif, Frankreich
,
T-Y Kim
6   Seoul National University College of Medicine, Seoul, Korea, Republik
,
M Kudo
7   Kindai University Faculty of Medicine, Department of Gastroenterology and Hepatology, Osaka, Japan
,
HY Lim
8   Samsung Medical Center, Sungkyunkwan University School of Medicin, Department of Medicine, Seoul, Korea, Republik
,
V Breder
9   Russian Cancer Research Center by NN Blikhin, Moscow, Russische Föderation
,
P Merle
10   Hospital La Croix-Rousse, Lyon, Frankreich
,
A Kaseb
11   The University of Texas MD Anderson Cancer Center, Department of Hemopathology, Houston, Vereinigte Staaten von Amerika
,
D Li
12   City of Hope Comprehensive Cancer Center and Beckman Research Institute, Department of Medical Oncology, Duarte, Vereinigte Staaten von Amerika
,
Y-H Feng
13   Division of Hematology and Oncology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan, Republik China
,
W Verret
14   Genentech, Inc., South San Francisco, Vereinigte Staaten von Amerika
,
A Nicholas
14   Genentech, Inc., South San Francisco, Vereinigte Staaten von Amerika
,
L Li
15   Roche Product Development, Shanghai, China
,
N Ma
14   Genentech, Inc., South San Francisco, Vereinigte Staaten von Amerika
,
AX Zhu
16   Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, Vereinigte Staaten von Amerika
,
A-L Cheng
17   National Taiwan University Cancer Center, Taipei, Taiwan, Republik China
› Institutsangaben